All News

2018

December

Media Release / Dec 08, 2018

Novartis data demonstrates consistent efficacy and tolerability of Kisqali® combination therapy in HR+/HER2- advanced breast cancer in patients with difficult-to-treat visceral disease

Read More

November

Media Release / Nov 16, 2018

Novartis receives positive CHMP opinion to expand Kisqali® combination therapy to all women with HR+/HER2- locally advanced or metastatic breast cancer

Read More
Media Release / Nov 02, 2018

Novartis data at ASH and SABCS show strength of pipeline and portfolio in hematology and oncology

Read More

July

Media Release / Jul 18, 2018

Novartis Kisqali® now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women

Read More

June

Media Release / Jun 03, 2018

Third Novartis Phase III trial shows Kisqali® combination therapy significantly improves PFS in HR+/HER2- advanced breast cancer

Read More

May

Media Release / May 17, 2018

Novartis data at ASCO and EHA reinforce company's commitment to reimagining cancer

Read More
Media Release / May 16, 2018

At the Meet Novartis Management investor event, Novartis highlights strategy to focus the company and drive sustainable growth

Read More

March

Media Release / Mar 20, 2018

Novartis teams up with Harvard to develop next generation biomaterial systems to deliver immunotherapies

Read More
Media Release / Mar 01, 2018

Novartis and Pear Therapeutics to develop digital therapeutics for patients with schizophrenia and multiple sclerosis

Read More

January

Media Release / Jan 03, 2018

Novartis Kisqali® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer

Read More

Pages

Related Links

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society report.

Learn More